KR100510174B1 - Composition for treating myeloid leukemia and increasing immunity comprising Salicornia herbacea extracts. - Google Patents

Abstract

The present invention relates to a myeloid-based leukemia treatment and immuno-enhancing composition comprising a seaweed extract, the composition for the treatment of myeloid-based leukemia and various diseases with excellent therapeutic effect without the underlying side effects such as toxicity to bone marrow cells. It can provide a composition for immuno-enhancing that can be utilized for treatment and prevention.

Description

Composition for treating myeloid leukemia and increasing immunity comprising Salicornia herbacea extracts.

The present invention relates to a myeloid-based leukemia treatment and immuno-enhancing composition comprising a seaweed extract.

Hamcho (Salicornia herbacea L.) is a native plant growing in colonies on the tidal-flat of the west coast of Korea. Hamchoes have the characteristics of fossil plants, and normal plants grow well in harsh environments where they cannot live. Hamchos are salty because they grow on tidal flats that contain many minerals and salts. Salt in the seaweed is very good for metabolism to sustain human life. In addition, according to a research report published by the National Institute of Maritime Affairs and Fisheries, the seaweed contains many kinds of organic materials useful for the human body, and inorganic and various minerals such as iron, calcium, magnesium and phosphorus. Seaweed removes intestinal stool and has an excellent intestinal cleansing effect. Seaweed has excellent effects on back pain, diabetes, thyroiditis and bronchitis. Hamcho contains a variety of substances with excellent efficacy. When sweating and fatigue, chewing on the seaweed immediately gives a feeling of vitality, and it has been used for a long time for food.

In the case of human leukemia, the most frequent expression is myeloid leukemia, and since leukemia is inoperable, anticancer chemotherapeutic agents are used for treatment or radiation irradiation. However, anticancer chemotherapeutic agents have inherent toxicity to bone marrow cells, and radiation therapy is inevitable to toxicity to bone marrow cells.

Myeloid myoblasts are known to be differentiated in the order of monoblast, promonocyte, monosite, and macrophages. Myeloid-based leukemia cells have been transformed into cancer cells at any stage in which bone marrow stem cells differentiate into macrophages. Macrophages are end staged cells that are finally differentiated and have properties that can no longer proliferate. Therefore, if a drug is developed that can differentiate myeloid-based cancer cells into macrophages, it is expected to be very useful as a new drug for the treatment of leukemia, but such a drug has not yet been developed and used in clinical practice.

Enhancement of the immune response in the treatment of cancer is just as important as any other therapy, such as chemotherapy or radiation therapy. Enhancing the immune response enhances our own biological defenses, so it is not only expected that it can be developed as a treatment without the underlying side effects such as toxicity to bone marrow cells. The reduced and inversely proportional decrease in immune response and the incidence of cancer indicate that enhanced biodefense is essential for the prevention and cure of these diseases.

Macrophages are distributed in all living tissues and have a strong phagocytosis, which is important not only as a scavenger of pathogens and dead cells, but also essential for inducing specific immunity by acting as antigen presenting cells. It is a cell. The importance of macrophages in the induction of immune responses demonstrates that most of the currently developed immunopotentiators primarily activate the function of macrophages and exhibit immunopotentiation.

 Therefore, in the treatment of leukemia, the drug having the effect of inducing the differentiation of leukemia cancer cells and activating the function of the microphage can be very useful as a treatment without the underlying side effects such as toxicity to bone marrow cells. This is an important task given to the art.

The present inventors completed the present invention by confirming that the seaweed extract has the effect of inducing the differentiation of myeloid-based leukemia cancer cells and activating the function of the microphage while studying the efficacy of the seaweed extract.

Therefore, an object of the present invention is to provide a composition for treating myeloid-based leukemia having excellent therapeutic effect without any underlying side effects such as toxicity to bone marrow cells.

In addition, an object of the present invention is to provide a composition for immuno-enhancing excellent effect of activating the function of the microphage.

The present invention relates to a myeloid-based leukemia treatment and immuno-enhancing composition comprising a seaweed extract.

The composition of the present invention may be administered alone or in combination with other leukemia treatment medicines as a composition for treating leukemia.

In addition, the composition of the present invention can be used alone or in combination with other drugs as an immuno-enhancing composition for the treatment and prevention of various diseases.

Seaweed extract has the effect of inducing differentiation and macrophage function of myeloid-type cancer cells, which are most frequently expressed in human leukemia. Macrophages are distributed in all living tissues and have a strong phagocytosis, which is important not only as a scavenger of pathogens and dead cells, but also essential for inducing specific immunity by acting as antigen presenting cells. It is a cell.

In the present invention, the seaweed extract is extracted in the form of seaweed juice and polymer sugar and protein.

First, the extract in the form of seaweed juice is 단계) step of washing the seaweed with clean drinking water 2-3 times to pass through the chopped, ii) high-pressure water bath containing the finely crushed seaweed solution and seaweed crushed by passing through the microwave After heating in a sterilizer for 1 to 2 hours without pressure, applying a heat of 80-110 ° C. for 20 to 60 minutes under 1 to 2 atmospheres, i) squeezing the wet seaweed and the juice with a press, and then Transferring only the juice to the automatic roll packing machine, i) Obtaining the packaged juice including sterilizing for 5-30 minutes with 100 ℃ hot water.

When the juice is packed, a lot of bubbles are generated in the process, so it is preferable to use a roll packing machine capable of minimizing the amount of bubbles generated when the juice is contained in the container. The lack of foam makes the air less likely to enter, making it easier to store it for a long time without deterioration.

The chopped soybeans used in the juice process are made of titanium alloy to rotate the blades alternately, which can effectively crush the harvested seaweeds harvested in late July ~ early September when the core is strong and coarse. It is made of completely harmless material.

The extract of the polymer sugar and protein form of the seaweed is iii) drying the seaweed to obtain a dry powder, ii) adding distilled water 5-10 times the weight of the dry powder, and heating at 90-100 ° C. for 3 hours, followed by filtration. Separating the aqueous layer and concentrating under vacuum at 35-45 ° C., iii) adding 1-5 times of ethanol and leaving it at low temperature for 10-14 hours to obtain a polymer precipitate, iii) centrifuging the precipitate. After harvesting, lyophilization is obtained.

The immunopotentiator obtained in this way is a polymer having a molecular weight greater than 30,000 daltons, galactose is the major monosaccharide, and alanine is the major amino acid.

The composition of the present invention can be administered alone or in combination with other leukemia treatment drugs such as Imatinib, Tretinoin, etc., in this case, it is possible to treat leukemia more efficiently. .

Since the composition of the present invention functions to activate the function of macrophages as an immuno-enhancing composition, it can be used alone or in combination with other forms of medicine to treat and prevent various diseases. For example, when administered with interferon-gamma, a synergistic immunostimulating effect is shown.

The composition for treating leukemia and the composition for boosting immunity of the present invention may vary depending on the age, sex, and weight of the patient, but may be administered 1 to 4 times a day, and the single dose of the perilla extract may vary depending on the form of the extract. It is preferable that the ethanol juice is 10-200 ml, and the polymer sugar and protein are 0.05-4.0 g.

The leukemia treatment and immuno-enhancing composition of the present invention may be composed only of the extract of seaweed, and may also be formulated in various forms of dosage forms when it contains a pharmaceutically acceptable carrier, excipient, and / or additive. That is, the leukemia treatment and immuno-enhancing composition of the present invention may include excipients such as lactose and starch, lubricants such as magnesium sterate, emulsifiers, suspending agents, isotonic and stabilizing agents, buffers and the like. It may include enteroabsorbents and / or flavoring agents. In addition, the compositions according to the invention may be formulated in oral or parenteral formulations. That is, the composition according to the present invention may be formulated in the form of oral dosage forms such as conventional tablets, capsules, solutions, and syrups, and may be formulated in the form of parenteral formulations such as injections.

The leukemia treatment and immunopotentiation composition of the present invention may be prepared in a beverage form. The composition in the form of the beverage is preferably diluted to distilled water and containing 10 to 80% by volume of the equivalent of the above-mentioned once-time of the juice or polymer sugar and protein. As an additive, liquid fructose and citric acid may be mixed and used. In addition, sugar or glucose may be used instead of liquid fructose, acetic acid or malic acid may be used instead of citric acid, or a mixture thereof may be used. The composition of the present invention in the form of a beverage can be used for the purpose of the prevention, treatment and immune boosting of leukemia.

In addition, the composition of the present invention can be used in various foods in addition to beverages. Examples of the food to which the seaweed extract can be added include tea and health supplements.

The seaweed has been used for a long time as an edible plant, so it is safe for the human body, so there is no concern about side effects such as cytotoxicity.

The present invention will be described in more detail with reference to the following Examples.

The following examples illustrate the invention, but the scope of the invention is not limited by the examples.

Example 1 Preparation of Seaweed Juice

Clean the seaweed 2 ~ 3 times with drinking water, and then crush the seaweed with a chopper. The seaweed solution and the seaweed powder obtained in this process are put in a burlap bag and heated under pressureless pressure in an autoclave sterilizer for 1 hour. The pressure is 1.5 atm and further heated to about 110 ° C. for 25 minutes. The contents passed through this process are put into a press, squeezed out of the juice under pressure, and then the squeezed juice is transferred to an automatic packing machine for packaging. The packaged juice solution is sterilized for 10 minutes in 100 ℃ hot water.

Example 2 Isolation of Polymer Sugar and Protein from Seaweed

The hot seaweed was dried by hot air to obtain a dry powder, distilled water 10 times the weight of the dry powder was added, heated at 100 ° C. for 3 hours, filtered to separate an aqueous layer, and concentrated under reduced pressure at 45 ° C., followed by 1-2. Pear ethanol was added and left at low temperature for about 12 hours to obtain a precipitate. The precipitate was harvested by centrifugation and then lyophilized.

Formulation Example 1 Tablet

Seaweed extract of Example 2 250.0 mg

Lactose BP 250.0 mg

Starch BP 30.0 mg

Pregelatinized Corn Starch BP 15.0 mg

1.0 mg magnesium stearate

The seaweed extract of Example 2 was sieved and mixed with lactose, starch and pregelatinized corn starch, and then a suitable volume of purified water was added and granulated into a powder. The granules were dried and then mixed with magnesium stearate and compressed to prepare tablets.

Formulation Example 2: Capsule

Seaweed extract of Example 2 250.0 mg

Starch 1500 100.0 mg

Magnesium Stearate BP 1.0 mg

The seaweed extract of Example 2 was sieved, mixed with starch and magnesium stearate, and then filled into gelatin capsules to prepare capsules.

Formulation Example 3: Syrup

100.0 g of seaweed extract of Example 2

637.5 g per bag

2.0 g of sodium carboxymethylcellulose

0.28 g of methyl paraben

0.12 g of propylparaben

20 ml of ethanol

A solution in which sodium carboxymethylcellulose was dissolved in 400 ml of purified water was added to a solution of white sugar in 500 ml of purified water, followed by mixing. Methyl paraben and propyl paraben were added and dissolved therein, followed by ethanol and purified water to make 1000 ml. A syrup was prepared by suspending the seaweed extract of Example 2, which was sieved thereto.

Formulation Example 4 Injection

100.0 mg of seaweed extract of Example 2

Dilute sodium hydroxide pH 7.5 ~ 8.5

Sodium Chloride BP for Injection Up to 2ml

The seaweed extract of Example 2 was dissolved in a suitable volume of dilute sodium hydroxide solution to adjust pH to 7.5-8.5, followed by volume adjustment using sodium chloride BP for injection, followed by thorough mixing. The solution was filled into a 2 ml type ampoule of clear glass, filled under dissolution of the glass by dissolving the glass and then sterilized in an autoclave to prepare an injection.

Formulation Example 5: Beverage

After diluting 10 ml of the vinegar juice with distilled water to make 80 ml, 7 to 10 wt% of liquid fructose and 0.1 to 0.2 wt% of citric acid were added thereto to prepare a mixed beverage of 100 ml.

Formulation Example 6: Beverage

After diluting the polymer sugar and protein 0.1g with distilled water to make 80 ml, 7 to 10% by weight of liquid fructose and 0.1 to 0.2% by weight of citric acid were added to prepare a mixed drink of 100 ml.

Experimental Example 1: Physicochemical Properties of Polymer Sugar and Protein Extracted from Seaweed

The physicochemical properties of the polymer sugar and protein extracted in Example 2 were investigated.

⑴ molecular weight estimation

The sample was dissolved in H ₂ O and filtered through a micropartition system (MPS-1) to estimate the molecular weight of the active material. As a result, it was found that the material was a high molecular weight material having a molecular weight greater than 30,000 Daltons.

조성 Sugar composition

As a pretreatment method for measuring the composition of monosaccharides contained in the sample, it was treated with 6N HCl for 4 hours at 100 ° C. for hydrolysis of amino sugars, and 2M triple for hydrolysis of neutral sugars. Treated with trifluoroacetic acid at 100 ℃ again for 4 hours. Analyzes were performed using Bio-LC DX-300 from Dionex, USA, and columns were used with Carbopac PA1 (4.5 × 50 mm) and detection was integrated. It was made by PID2 with integrated amperometry. These results are summarized in Table 1.

Composition of Monosaccharides in Samples Party nmole / 95 µg ng / 95µg  Fucose 0.88 144 Galactosamine 0.18 31 Glucosamine 0.84 150 Galactose 16.75 3,018 Glucose 4.96 894 Mannose 3.41 614

⑶ composition of amino acids

The composition of amino acids contained in the samples was analyzed by hydrolysis and PITC labeling using the PICO-tag method. The analyzer was HPLC and the detector was a waters 996 photodiode array detector (PDA, 254 nm) and the column was a waters Pico-tag column (3.9 × 300 mm, 4 μm). ) Was used. These results are summarized in Table 2.

The composition of free amino acids in the sample amino acid pmol / 290 μg Cysteine 624.162 Aspartic Acid + Asparagine 1910.181 Glutamic Acid + Glutamine 1792.619 Serine 875.061 Glycine 1548.964 Histidine 320.133 Arginine 336.355 Threonine 351.626 Alanine 3399.850 Proline 796.270 Tyrosine 183.211 Valine 863.826 Methionine 197.784 Cystine 30.179 Isoleucine 387.406 Leucine 507.424 Phenylalanine 157.971 Tryptophan 13.107 Lee Sin 372.305

Experimental Example 2: Induction of Differentiation of Myeloid Cancer Cells

Differentiation-inducing activity against Raw 264.7, a myeloid cancer cell, was observed. Cells were added to 5 × 10 ⁵ cells / well in a 24-well culture dish, and the extracts of Examples 1 and 2 were added in amounts of 0.05% by volume and 10 μg / ml, respectively, relative to the culture solution. After 48 hours of incubation, it was examined using an optical microscope.

As a result, the myeloid-based cancer cells in the form of before and after the treatment (A) and after treatment (B) of the polymer sugar and protein of FIG. Differentiation is induced by macromolecular sugars and proteins (10 μg / ml) isolated from juice stock or grasswort, and its shape becomes fibroblast-like, strong adhesion to plastic surface, and many vacuoles It could be observed to produce.

Myeloid cancer cells are differentiated into macrophages to prevent further proliferation.

Experimental Example 3: Inhibitory Effect of Proliferation on Myeloid Cancer Cells

Differentiation-inducing activity against Raw 264.7, a myeloid cancer cell, was observed. Cells were added to a 96-well microtiter plate at 2 × 10 ⁴ cells / well, and then the extracts of Example 1 were added to 1, 1/3, 1/9, 1/27, 1/81, Dilute to 1/243 and 1/729 times and add 0.05% by volume to the culture, and the extract of Example 2 was added at concentrations of 200, 70, 20, 7, 2.5, 0.8 and 0.3 μg / ml, respectively for 2 days It was. The degree of proliferation of the cells was measured by adding [3H] -thymidine to the cell culture medium, followed by further incubation for 6 hours, and then harvesting the cells to determine the amount of [3H] -thymidine introduced into the cells. microbetacounter).

As a result, as shown in Figs. 3 and 4, the polymer sugar and protein isolated from the perilla juice or perilla inhibited the proliferation of cancer cells in a concentration-dependent manner. Therefore, it was confirmed that the high molecular sugar and protein isolated from the persimmon juice or seaweed described in the present invention induced differentiation of Raw 264.7, a myeloid cancer cell, thereby inhibiting proliferation.

Experimental Example 4: Efficacy promoting effect

Raw 264.7, a myeloid-based cancer cell, was added to a 2-well chamber slide at 1 × 10 ⁵ cell / ml, and the extracts of Examples 1 and 2 were 0.05% by volume and 10µg / ml, respectively. It was added in the amount of and incubated for 48 hours to differentiate into macrophages. To this, sensitized sheep blood cells (antibodies to sheep sheep cells diluted 1: 256) were added, reacted at 37 ° C. for 30 minutes, washed twice with physiological saline, and then suspended in physiological saline at 1%. After incubation at 37 ° C. for 1 hour with 50 μl, the undeveloped sheep cells were removed with ACK Lysis buffer and stained with Wright and Giemsa solutions. It was observed under a microscope.

As a result, from the persimmon juice stock solution or seaweed in the state before (A) and after treatment (B) of the juice of the juice of FIG. 5 and before (A) and after treatment (B) of the polymer sugar and protein of FIG. The isolated macromolecular sugar and protein (10 ㎍ / ml) was confirmed to increase the phagocytosis for sheep red blood cells strongly. Therefore, the polymer sugar and protein isolated from the perilla juice or seaweed described in the present invention is expected to exhibit an anticancer effect by strongly enhancing the phagocytosis, which is one of the most representative functions of macrophages, and promoting the induction of immune responses.

Experimental Example 5: IL-1β Production Promoting Effect

Samples were added to Raw 264.7, a myeloid cancer cell, and cultured for 48 hours to differentiate into macrophages. That is, the cells were added to a 24-well culture plate at 5 × 10 ⁵ cells / well, and then the extract of Example 1 was diluted 1, 1/3, 1/9, 1/27 and 1/81 times, respectively, to the culture medium. 0.05 volume% and the extract of Example 2 were added at concentrations of 100, 33, 11, 3.7 and 1.2 μg / ml, respectively. After 48 hours of incubation, the culture filtrate was obtained. The amount of IL-1β contained in the culture filtrate was measured using an R & D ELISA kit.

As a result, as shown in Figures 7 and 8, the polymer sugar and protein isolated from the perilla juice or perilla promoted the production of IL-1β in a concentration-dependent manner. Therefore, it is expected that the macromolecular sugars and proteins isolated from the persimmon juice or seaweed described in the present invention will induce the production of IL-1β by the macrophages and exhibit anticancer effects.

Experimental Example 6: TNF-α production promoting effect

Samples were added to Raw 264.7, a myeloid cancer cell, and cultured for 48 hours to differentiate into macrophages. That is, cells were added at 5 × 10 ⁵ cells / well to a 24-well culture plate, and then the extracts of Example 1 were 1, 1/3, 1/9, 1/27, 1/81 and 1/243 times, respectively. Diluted and added to 0.05% by volume relative to the culture, the extract of Example 2 was added at a concentration of 100, 33, 11, 3.7, 1.2 and 0.4 ㎍ / ml, respectively. After 48 hours of incubation, the culture filtrate was obtained. The TNF-α content in the culture filtrate was measured using an ELISA kit from Pharmingen.

As a result, as shown in Figs. 9 and 10, the polymer sugar and protein isolated from the perilla juice or perilla promoted the production of TNF-α in a concentration-dependent manner. Therefore, the polymer sugar and protein isolated from the perilla juice or perilla described in the present invention is expected to exhibit the anti-cancer effect by inducing the production of TNF-α macrophages.

Experimental Example 7: NO Production Promoting Effect

Samples were added to Raw 264.7, a myeloid cancer cell, and cultured for 48 hours to differentiate into macrophages. That is, the cells were added to the 24-well culture plate at 5 × 10 ⁵ cells / well, and then the extracts of Example 1 were respectively 1, 1/3, 1/9, 1/27, 1/81, 1/243 and Diluted by 1 / 729-fold and added to 0.05% by volume relative to the culture, the extract of Example 2 was added at a concentration of 100, 33, 11, 3.7, 1.2, 0.4 and 0.14 μg / ml, respectively. After 48 hours of incubation, the culture filtrate was obtained. The amount of NO contained in the culture filtrate was equal to 50 µl of the cell culture and 0.5 equivalent sulfinylamide in 0.05% H ₃ PO ₄ , 0.05% N- (1-naphthyl) -ethylenediamine Dihydrochloride) was mixed in a 96-well microtiter plate and reacted at room temperature for 5 minutes, and then measured at 550 nm using an ELISA reader.

As a result, as shown in Figs. 11 and 12, the polymer sugar and protein composition isolated from the perilla juice or perilla promoted the production of NO in a concentration-dependent manner. Therefore, it is expected that the macromolecular sugars and proteins isolated from the seaweed juice or seaweed described in the present invention will induce the production of NO by macrophages and exhibit anticancer effects.

Experimental Example 8 Combined Effect with Interferon-gamma

Raw 264.7 cells, which are myeloid cancer cells, were added to the 24-well culture plate at 5 × 10 5 cells / well, and then the extract of Example 2 was 100, 33, 11, 3.7, 1.2 and 0.4 μg / Additional interferon-gamma was added at 10 units / ml to the addition of ml or to extracts of Example 2 at concentrations of 100, 33, 11, 3.7, 1.2 and 0.4 μg / ml, respectively. After 48 hours of incubation, the culture filtrate was obtained. The amount of NO contained in the culture filtrate was equal to 50 µl of the cell culture and 0.5 equivalent sulfinylamide in 0.05% H ₃ PO ₄ , 0.05% N- (1-naphthyl) -ethylenediamine Dihydrochloride) was mixed in a 96-well microtiter plate and reacted at room temperature for 5 minutes, and then measured at 550 nm using an ELISA reader.

As a result, as shown in Fig. 13, the polymer sugar and protein composition isolated from the seaweeds promoted the production of NO by using in combination with interferon. The effect of NO production enhancement by combination with interferon-gamma was more evident in very low concentrations of polymer sugar and protein composition isolated from seaweed.

As can be seen from the above experimental example, the perilla extract has an effect of promoting differentiation and macrophage function activation of myeloid cancer cells. Accordingly, the present invention can provide a composition for treating myeloid-based leukemia, which has excellent therapeutic effect and no immune side effects such as toxicity to bone marrow cells, and an immune enhancing composition that can be used for the treatment and prevention of various diseases. .

Figure 1 shows the morphological changes according to the differentiation induction of myeloid-based cancer cells by the seaweed juice (before (A) and after treatment (B)).

Figure 2 shows the morphological changes according to the induction of differentiation of myeloid-based cancer cells by the polymer sugar and protein isolated from seaweed (polymer sugar and protein before (A) and after treatment (B)).

Figure 3 shows the proliferation inhibitory effect according to the differentiation of myeloid-based cancer cells by the seaweed juice.

Figure 4 shows the proliferation inhibitory effect of the differentiation of myeloid-based cancer cells by the polymer sugar and protein isolated from the seaweed.

Figure 5 shows the effect of enhancing the phagocytosis of seaweed juice (prior to the juice juice (A) and after treatment (B)).

Figure 6 shows the phagocytosis enhancing effect of the polymer sugar and protein isolated from the seaweed (polymer sugar and protein before (A) and after treatment (B)).

Figure 7 shows the effect of promoting the production of IL-1β juice.

Figure 8 shows the IL-1β production promoting effect of the polymer sugar and protein isolated from the seaweed.

Figure 9 shows the effect of promoting the TNF-α production of seaweed juice.

Figure 10 shows the TNF-α production promoting effect of the polymer sugar and protein isolated from the seaweed.

Figure 11 shows the effect of promoting the production of NO.

Figure 12 shows the NO production promoting effect of the polymer sugar and protein isolated from the seaweed.

Figure 13 shows the increase in the production of NO when co-administered with interferon-gamma and polymer sugar and protein isolated from seaweed.

Claims (4)

 Myeloid-based leukemia treatment and immuno-enhancing composition comprising a seaweed extract. The method of claim 1, wherein the seaweed extract iii) cleansing the seaweed 2 to 3 times with drinking water and passing it through a chopped wave, ii) putting the crushed vinegar liquor and crushed seaweed powder through the chopped soak into burlap cloth After heating in a sterilized sterilizer for 1 to 2 hours without pressure, applying a heat of 80 to 110 ℃ for 20 minutes to 60 minutes under 1 to 2 atmospheres, i) squeezing the wet seaweed and the juice with a press, Transporting only the juice to an automatic roll packer for packaging; i) disinfecting the packaged juice with hot water at 100 ° C. for 5 to 30 minutes, for treating myeloid-based leukemia and immunity enhancement. Composition The method according to claim 1, wherein the seaweed extract comprises: i) hot air drying the seaweed to obtain a dry powder; ii) adding distilled water 5-10 times the weight of the dry powder, and heating at 90-100 ° C. for 3 hours, followed by filtration Separating and then vacuum concentrating at 35-45 ° C., iii) adding 1-5 times of ethanol and leaving it at low temperature for 10-14 hours to obtain a polymer precipitate, iii) harvesting the precipitate by centrifugation. After, lyophilization, the composition for treating and enhancing myeloid leukemia, characterized in that the separated polymer sugar and protein The composition for treating leukemia and immunopotentiation according to any one of claims 1 to 3, which is prepared in the form of a beverage.